The 2026 AACR New Drugs on the Horizon session highlighted TRI-611, an FDA Fast Track-designated CNS-penetrant CRBN-mediated molecular glue degrader for ALK fusion-positive non-small cell lung cancer. TRI-611 recruits a non-G-loop degron distal to the ALK orthosteric site, which the company says supports an active site-independent strategy—aimed at overcoming resistance to ALK tyrosine kinase inhibitors and limited post-TKI options. The program is in Phase 1/2 evaluation. The disclosure at AACR positions TRI-611 within the growing molecular glue and targeted degradation pipeline space, where differentiating mechanisms and CNS exposure can be decisive for efficacy in resistant disease. For biotech stakeholders, the Fast Track designation and early-phase development keep attention on next-generation ALK degradation approaches, particularly where resistance mechanisms limit standard treatments.